Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Cervical carcinoma and other human papillomavirus (HPV)-induced cancers represent a significant global health challenge, necessitating innovative treatment strategies.
• While immunotherapy offers potential for HPV infections and related lesions, prior efforts targeting cytotoxic CD8+ T cells (CTLs) have lacked clinical success.
• CD4+ T cells are critical for CTL response induction/maintenance and direct anti-tumor immunity, driving interest in human leukocyte antigen (HLA) class II-restricted epitopes for improved HPV immunotherapy.

Purpose of the Study:

• To identify promiscuous HPV16-derived CD4+ T helper epitopes capable of eliciting T cell immunity in a broad population segment.
• To evaluate the potential of these epitopes for developing a comprehensive therapeutic HPV vaccine.

Main Methods:

• Combined HLA class II epitope prediction servers with in vitro immunological assays.
• Identified CD4+ T cell epitopes derived from HPV16 proteins (E2, E5, E6, and E7).
• Assessed epitope restriction by HLA-DR molecules and T cell responses using interferon (IFN)-γ ELISPOT and cytokine secretion assays.

Main Results:

• Identified HPV16-derived epitopes restricted by up to nine HLA-DR molecules.
• Demonstrated that these epitopes induce frequent and robust HPV16 peptide-specific Th1 responses in healthy donors.
• Observed specific IFN-γ T cell responses to these peptides in blood samples from patients with HPV16+ CIN2/3 and cervical carcinoma.

Conclusions:

• The identified T helper epitopes are promising candidates for therapeutic HPV vaccine development.
• These epitopes can induce significant T cell immunity in both healthy individuals and patients with HPV-associated lesions/cancer.
• This approach offers a potential strategy to overcome limitations of previous HPV immunotherapies.